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a b s t r a c t
The phosphatidylinositol-3-kinase (PI3K)-Akt signaling pathway regulates several key cellular functions
including protein synthesis, cell growth, glucose metabolism, and inﬂammation. Many viruses have
evolved mechanisms to manipulate this signaling pathway to ensure successful virus replication. The
human herpesviruses undergo both latent and lytic infection, but differ in cell tropism, growth kinetics,
and disease manifestations. Herpesviruses express multiple proteins that target the PI3K/Akt cell
signaling pathway during the course of their life cycle to facilitate viral infection, replication, latency,
and reactivation. Rare human genetic disorders with mutations in either the catalytic or regulatory
subunit of PI3K that result in constitutive activation of the protein predispose to severe herpesvirus
infections as well as to virus-associated malignancies. Inhibiting the PI3K/Akt pathway or its down-
stream proteins using drugs already approved for other diseases can block herpesvirus lytic infection and
may reduce malignancies associated with latent herpesvirus infections.
Published by Elsevier Inc.
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Introduction
The phosphatidylinositol-3-kinase (PI3K)-Akt signaling path-
way regulates multiple key cellular functions including protein
synthesis, cell growth, glucose metabolism, and inﬂammation.
Viruses are obligatory intracellular pathogens and they usurp host
functions for viral gene transcription and translation, genome
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replication, and progeny virion production. Viruses also suppress
host cell stress responses induced by accumulation of viral proteins,
free DNA ends associated with virus replication, nutrient and energy
depletion, or hypoxia. To manipulate the intracellular environment
for optimal viral replication, viruses including the human herpes-
viruses, have evolved multiple ways to hijack cellular signaling
pathways that are critical for maintaining normal cellular functions
such as mitogen-activated protein kinase (MAPK), NF-κB, JAK/STAT,
and PI3K/Akt pathways. There are eight human herpesviruses-
herpes simplex virus (HSV)-1 and -2, varicella zoster virus (VZV),
cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus
(HHV)-6 and HHV-7, and Kaposi sarcoma-associated herpesvirus
(KSHV, HHV-8). Each of these viruses replicate in the nucleus and
have dual life cycles- lytic replication and latent infection. They
encode from about 70 (in the case of VZV) to over 200 (in the case of
CMV) proteins, and differ in cell tropism, replication kinetics, and
disease manifestations. Like other viruses, human herpesviruses
exploit the PI3K/Akt pathway to optimize virus entry, replication,
latency, reactivation, and modulation of host innate immune
responses (reviewed in (Alwine, 2008; Bhatt and Damania, 2012;
Buchkovich et al., 2008; Cooray, 2004; Diehl and Schaal, 2013; Dunn
and Connor, 2012; Tsalikis et al., 2013; Walsh and Mohr, 2011)). Here
we highlight recent ﬁndings on the ability of human herpesviruses to
modulate the PI3K/Akt signaling pathway, the effects of mutations in
PI3K on herpesvirus infections in humans, and potential strategies to
inhibit PI3K to treat herpesvirus infections and virus-associated
malignancies.
The PI3K/Akt pathway
PI3K is activated when extracellular stimuli such as cytokines,
growth factors, or viruses bind to cell surface receptors such as G
protein coupled receptors (GPCRs), B cell receptors (BCR), or integrins
that have tyrosine kinase activity (Fig. 1). This results in translocation
of the PI3K complex, which usually consists of a p85 regulatory
domain and a p110 catalytic domain, from the cytoplasm to the
plasma membrane. Binding of the phosphorylated tyrosine residues
on receptors or adapter proteins to the p85 regulatory subunit of
PI3K relieves its inhibitory activity on the p110 catalytic domain
of PI3K (Cuevas et al., 2001) and allows p110 to phosphorylate
membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) to
generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). This results
in recruitment of pleckstrin homology domain containing proteins,
including phosphoinositide-dependent protein kinase 1 (PDK1) and
the proto-oncoprotein serine/threonine kinase Akt to PIP3 to the
plasma membrane. PDK1 phosphorylates Akt at threonine 308, and
the mammalian target of rapamycin (mTOR) complex 2 (mTORC2)
phosphorylates Akt at serine 473 site to fully activate Akt. PIP3 also
binds to its receptor on the endoplasmic reticulum (ER), leading to
calcium release from the ER, and activation of calcium signaling
which is important for cytoskeletal organization, ﬁlopodia formation,
and cell–cell fusion.
Activated Akt induces phosphorylation of multiple downstream
targets. Phosphorylation of cell cycle inhibitors p21Cip1 and p27Kip1
inactivates these proteins and enhances progression of cells from
the G1 to S phase of the cell cycle. Phosphorylation and inactivation
of glycogen synthase kinase (GSK)-3β by Akt promotes cell growth.
Akt phosphorylation of pro-apoptotic proteins BAD, Bim, caspase 9,
and phosphorylation of the transcription factor FOXO1 results in
inactivation of these proteins and inhibits apoptosis. Similarly,
increased expression of the anti-apoptotic proteins X-linked inhi-
bitor of apoptosis protein (XIAP), Bcl-xL, Bcl-2, and myeloid cell
leukemia 1 (Mcl-1) by Akt enhances cell survival. Phosphorylation
and inactivation of the tuberous sclerosis protein 2 (TSC2) results
in mTOR1 activation which in turn phosphorylates and inhibits
the translational inhibitor eukaryotic translation initiation factor 4E
Fig. 1. Receptor-mediated activation of PI3K-Akt pathway and signaling. Binding of ligands to cell surface receptors induces activation of PI3K. Activated PI3K converts
membrane-bound PIP2 to PIP3. PTEN dephosphorylates PIP3 to form PIP2. PIP3 recruits PDK1 and Akt to the plasma membrane, resulting in Akt phosphorylation by PDK1.
Akt can be dephosphorylated by PP2A and PHLPP2. Activated Akt (a) stimulates protein synthesis by phosphorylation of mTOR inhibitor TSC2, leading to mTOR1 activation,
and phosphorylation of 4EBP1 (an inhibitor of translation) and S6K1, (b) stimulates cell cycle progression by phosphorylation of cell cycle inhibitors p21Cip1 and p27Kip1 for
their degradation, and phosphorylation and inactivation of transcriptional factors GSK-3β and FOXO3, leading to increased cyclin D1 and reduced p27Kip1 expression, and
(c) inhibits apoptosis by phosphorylation and inactivation of proapoptotic proteins BAD, Bax, caspase 9, and transcriptional factor FOXO3 to reduce Bim and FasL expression.
*indicates that idelalisib blocks PI3Kδ only.
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binding protein 1 (4EBP1) and activates S6K1 to stimulate protein
synthesis (Hassan et al., 2013; Hemmings and Restuccia, 2012;
Vanhaesebroeck et al., 2012).
PI3Ks are divided into three subclasses on the basis of struc-
ture, regulation, and lipid substrate speciﬁcity. Class I PI3Ks are
often involved in the pathogenesis of human cancers and are
extensively targeted by viruses (Engelman, 2009; Walsh and Mohr,
2011). Class I PI3Ks are heterodimers consisting of a p110 catalytic
subunit (p110α, β, δ, or γ) and a regulatory subunit (p50, p55, p85,
or p101). PI3K p110α and p110β are ubiquitously expressed,
whereas p110δ and p110γ are primarily found in white blood cells
(Okkenhaug, 2013).
PI3K/Akt activity is tightly controlled at multiple steps. PI3K
signaling is negatively regulated by several phosphoinositide
phosphatases, including the tumor suppressor phosphatase and
tensin homolog (PTEN) which dephosphorylates the 3-phosphate
from the inositol ring of PIP3 (Stambolic et al., 1998), inositol
polyphosphate-4-phosphatase, type II (INPP4B) which depho-
sphorylates the 4-position phosphate from the inositol ring of
PIP2, the PH domain and leucine rich repeat protein phosphatase 2
(PHLPP2) which dephosphorylates Akt at Ser 473 (Brognard
et al., 2007), and the protein phosphatase 2 (PP2A) which depho-
sphorylates Akt at Thr 308 (Andjelkovic et al., 1996; Kuo et al.,
2008).
Enhanced PI3K/Akt signaling has been identiﬁed in many
human cancers including mutation or ampliﬁcation of the genes
encoding catalytic subunits of PI3K p110α and p110δ the gene
product of PIK3CA and PI3KCD, respectively (Perez-Tenorio et al.,
2007; Samuels et al., 2004), loss of function of PTEN (Perez-
Tenorio et al., 2007), and/or INPP4B (Balakrishnan and Chaillet,
2013; Bertucci and Mitchell, 2013; Gewinner et al., 2009), or
mutation and/or ampliﬁcation of the proto-oncogenes AKT1and
AKT2 (Ruggeri et al., 1998; Staal, 1987). Therefore, the PI3K/Akt
pathway is an important target for drug development for treat-
ment of human malignancies as well as for virus infections.
Herpesviruses modulate the PI3K/Akt pathway
Herpesviruses enhance their replication by modulating the
intracellular environment through altering cell signaling pathways
to control transcription and translation, regulate cell cycle pro-
gression, inhibit apoptosis, evade host defense systems, and alter
cellular metabolism. Herpesvirus activation of the PI3K/Akt path-
way manipulates many of these activities to favor virus replication
or latency. Activation of PI3K/Akt signaling can occur at multiple
steps during the virus life cycle including (a) entry and virus
glycoprotein binding, (b) release of tegument proteins after virus
delivery into the cell, (c) virus replication, and (d) virus latency
and reactivation.
Entry of herpesviruses in cells induces activation of PI3K/Akt
Human herpesviruses infect different cell types including epithe-
lial and endothelial cells, macrophages, and lymphocytes. These
viruses can enter cells by viral glycoprotein binding to receptors
and fusion of viral and cellular membranes either at the cell surface
or after endocytosis. The envelope of human herpesviruses contains
several glycoproteins, including gB and gH/gL which are shared by all
herpesviruses and are essential for mediating membrane fusion.
Additional glycoproteins are important for entry of speciﬁc viruses
such as gD for HSV, gp350 and gp42 for EBV, and UL128, UL130, and
UL131A for CMV.
Binding of HSV virions to cellular receptors on the plasma
membrane induces changes in cellular gene expression resulting in
activation of PI3K/Akt, NF-κB and JAK/STAT signaling (MacLeod and
Minson, 2010). Activation of the PI3K/Akt signaling pathway is
required for HSV entry into cells. Chemical inhibition of PI3K activity
with LY294002 blocked HSV entry and fusion mediated by viral
glycoproteins (Tiwari and Shukla, 2010). Inhibition of PI3K with
wortmannin blocked trafﬁcking of HSV virions to the periphery of
the nucleus (Nicola and Straus, 2004). PI3K inhibition with LY294002
reduced expression of HSV-1 ICP0 and increased the cleavage of
caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP), imply-
ing that PI3K may reduce apoptosis in HSV-infected cells (Hsu et al.
2010). HSV infection triggers Akt phosphorylation within minutes
after infection (Cheshenko et al., 2013; Hsu et al., 2010; MacLeod and
Minson, 2010). Inhibiting Akt expression with siRNA or with milte-
fosine, which blocks Akt phosphorylation, inhibited virus-induced
release of calcium, HSV entry, and plaque formation (Cheshenko
et al., 2013). Deletion of HSV glycoprotein D (gD) or gB prevents
virus-induced Akt phosphorylation, and Akt interacts directly with
gB, but not with gD (Cheshenko et al., 2013) (Table 1).
Integrins serve as HSV entry mediators and HSV gH binds to αvβ3
integrin (Parry et al., 2005). The binding of gH to αvβ3 integrin
activates Akt and triggers intracellular calcium release (Cheshenko
et al., 2007; Cheshenko et al., 2014). Inhibition of integrin αvβ3
expression with siRNA reduced virus entry, calcium release, and
plaque formation. HSV deleted for gH binds to cells and activates Akt,
but is impaired for calcium signaling and virus entry. Activation of
Akt by HSV is followed by integrin signaling, release of intracellular
calcium, and phosphorylation of focal adhesion kinase (FAK) which
provides a favorable environment for entry of the virus into the cell
(Cheshenko et al., 2014). Binding of HSV-1 to cells also activates the
epidermal growth factor receptor (EGFR)- PI3K signaling pathway,
resulting in phosphorylation of coﬁlin and polymerization of actin
which facilitates virus entry (Zheng et al., 2014).
CMV attachment and receptor binding, like HSV, induces PI3K/
Akt signaling. CMV infection triggers PI3K activation in serum-
starved human embryonic lung ﬁbroblasts within the ﬁrst 30 min
of infection with UV-inactivated CMV. PI3K activation subsides
2 h after infection and resumes 4 h after infection (Johnson et al.,
2001; McFarlane et al., 2011). While CMV protein synthesis is
dispensable for the ﬁrst phase of PI3K activation, it is necessary for
the second phase of activation. Inhibition of PI3K with LY294002
delays CMV entry, and reduces immediate-early and early gene
expression, and viral DNA replication. Infection of cells with CMV
results in phosphorylation of platelet-derived growth factor recep-
tor (PDGFR)-α which interacts with the p85 subunit of PI3K and
activates Akt (Soroceanu et al., 2008). Akt activation may be
mediated by CMV gB binding to cells, since overexpression of gB
induces phosphorylation of Akt and PDGFR-α (Cobbs et al., 2014).
Treatment of cells with CMV neutralizing antibody reduced
Akt activation (Andreoni et al., 2002). HCMV activates PI3K/Akt
and inhibits apoptosis in monocytes by upregulating Mcl-1 (Chan
et al., 2010).
Entry of EBV and KSHV into cells also induces PI3K/Akt
signaling. EBV gp350 binding to CD21, the virus receptor on B
cells, triggers Akt and GSK-3β activation (Barel et al., 2003). The
interaction of KSHV glycoproteins with integrins induces phos-
phorylation of FAK and subsequently Src, PI3K, and c-Cbl
(Chakraborty et al., 2011; Krishnan et al., 2006; Naranatt et al.,
2003; Sharma-Walia et al., 2004; Valiya Veettil et al., 2010; Veettil
et al., 2006). KSHV gB induces phosphorylation of Akt (Sharma-
Walia et al., 2004; Zhang et al., 2005). PI3K is important for
induction of Cdc42 Rho and RhoA GTPases and cytoskeletal
changes in KSHV-infected cells (Sharma-Walia et al. 2004). PI3K
inhibition reduces infectivity and cytoskeletal changes associated
with KSHV gB, but does not affect virus binding to cells (Valiya
Veettil et al. 2010; Tiwari and Shukla, 2010). KSHV induces
phosphorylation of the p85 subunit of PI3K within one minute
of infection which returns to normal levels 30 min after infection
(Kerur et al., 2010).
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Herpesvirus tegument proteins activate PI3K/Akt
Herpesvirus tegument proteins are located between the viral
envelope and capsid and are released into the cell immediately
after virus entry. HSV encodes two tegument proteins, VP11/12
and US3 protein kinase, that modulate the PI3K/Akt pathway
(Benetti and Roizman, 2006; Eaton et al., 2014; Wagner and
Smiley, 2011). VP11/12, the most abundant HSV tegument protein,
is phosphorylated by Lck and interacts with the p85 subunit of
PI3K. VP11/12 is essential for activation of PI3K/Akt by HSV
(Wagner and Smiley, 2011). The carboxyl terminal region of
VP11/12 contains a PI3K p85 subunit binding domain (YTHM)
and two Src family kinase (SFK) motifs (YETV and YEEI) which
together are important for activation of Lck and binding to PI3K
p85 (Strunk et al., 2013).
HSV US3, one of two HSV encoded protein kinases, does not
share sequence homology with Akt or activate Akt directly, but
serves as an functional homolog of Akt and phosphorylates several
Akt substrates including GSK-3β, FOXO1, TSC2 (Chuluunbaatar
et al., 2010). Phosphorylation of TSC2 by US3 at the same sites as
those phosphorylated by Akt results in activation of mTORC1,
which enhances protein translation and HSV replication. Phos-
phorylation of GSK3β by US3 inactivates GSK3β and promotes
stable microtubule formation and virus spread (Naghavi et al.,
2013). Infection of cells with an HSV US3 null mutant results in
constitutive Akt activation. Deletion of US3 results in increased
phosphorylation of VP11/12 by SFKs and by the HSV UL13 protein
kinase (Eaton et al., 2014). Thus, US3 inhibits phosphorylation of
VP11/12 by SFKs and UL13 resulting in inhibition of VP11/12
signaling and Akt activation. While Akt is activated throughout
the entire replicative cycle during infection of cells with an HSV
US3 null mutant, Akt is only activated at early time points after
infection with wild-type HSV (Benetti and Roizman, 2006).
VZV infection activates Akt and inhibition of PI3K or Akt
reduces VZV replication (Rahaus et al., 2007; Sen et al., 2014).
Infection with VZV results in phosphorylation of downstream
targets of Akt including mTOR, FOXO1, 4EBP1, and S6K1. Expres-
sion of VZV protein kinases ORF47 and ORF66 increases Akt
activation; conversely VZV deleted for ORF47 and ORF66 results
in reduced phosphorylation of Akt and GSK-3β. The VZV ORF12
tegument protein associates with the p85 subunit of PI3K and
activates Akt at both threonine 308 and serine 473 (Liu and Cohen,
2013). Activation of Akt by ORF12 protein is important for cell
cycle progression in VZV-infected cells, since inhibition of Akt
activity reduces the differences observed in cell cycle progression
with wild-type and ORF12 deleted VZV. The role of CMV, EBV, and
KSHV tegument proteins in activating the PI3K/Akt pathway has
not been reported.
Activation of the PI3K/Akt pathway by herpesvirus proteins expressed
during virus replication
While entry of herpesviruses into cells and subsequent release
of tegument proteins can transiently activate the PI3K/Akt path-
way, viral protein synthesis is required to sustain activation of
PI3K/Akt. HSV‑2 UL39 encodes the large subunit of HSV ribonu-
cleotide reductase (ICP10) which contains an amino terminal
serine–threonine protein kinase domain (ICP10PK). ICP10PK func-
tions as a constitutively activated growth-factor receptor that
activates PI3K/Akt and Ras/ERK pathways (Laing et al., 2008;
Laing et al., 2010; Smith, 2005). While ICP10PK mediated PI3K
activation was initially believed to responsible for preventing
apoptosis in HSV-2 infected cells (Laing et al., 2008; Laing et al.,
2010; Perkins et al., 2002a; Perkins et al., 2002b), more recent
studies indicate that ICP10PK protects cells from apoptosis by
binding to caspase-8 and disrupting its interaction with FADD,
which is independent of activation of PI3K (Dufour et al., 2011).
These observations are supported by the fact that the HSV-2
homolog of UL39 in HSV-1 (ICP6) does not have similar serine-
threonine kinase activity and does not activate Akt, but also binds
Table 1
Herpesvirus proteins that modulate the PI3K/Akt pathway.
Virus
protein
Location in virus, expression
kinetics
Cellular target for viral protein Effect of modulating PI3K/Akt signaling
HSV1 gB Envelope, γ Akt, PILRα, Virus entry
gD Envelope, γ Nectin-1, HVEM, 3-OS HS Virus entry
gH Envelope, γ integrins Virus entry
VP11/12 Tegument, γ Lck, p85 subunit of PI3K
US3 Tegument, γ GSK-3, FOX1, TSC2 Protein translation
LAT Latency Latency
HSV2 ICP10 Lytic, β caspase-8 Anti-apoptosis
VZV ORF12 Tegument, γn p85 subunit of PI3K Cell cycle progression
ORF47 Tegument, γn
ORF66 Tegument, γn
HCMV gB Envelope, γ integrins Virus entry
IE1 Lytic, α Anti-apoptosis
IE2 Lytic, α Anti-apoptosis
EBV gp350 Envelope, γ CD21 Virus entry
BRLF1 (Rta) Lytic, α Reactivation from latency
LMP1 Latency CD40 mimic, TRAFs, p85 subunit of
PI3K
Anti-apoptosis, protein translation, transformation
LMP2A Latency BCR mimic, Syk, Lyn, Shb Anti-apoptosis, protein translation
EBNA-2 Latency p55α subunit of PI3K B cell proliferation
KSHV gB Lytic, γ* Integrins Virus entry
K1 Lytic, β, low level expression in
latency
BCR mimic, p85 subunit of PI3K, Syk,
Lyn
Anti-apoptosis, protein translation
vGPCR Lytic, β GPCR mimic Anti-apoptosis, protein translation
vIL-6 Lytic, β, low level expression in
latency
IL-6 mimic (binds to gp130) Anti-apoptosis; Reprogramming of endothelial cells to lymphatic
cells
Rta Lytic, α Reactivation from latency
PILRα, paired immunoglobulin-like type 2 receptor-α; HVEM, herpesvirus entry mediator; 3-OS HS, 3-O-sulfated heparan sulfate.
n Putative kinetic assignment, inferred from its homolog in HSV.
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caspase-8 and blocks apoptosis (Chung et al., 1989; Dufour et al.,
2011).
While activation of Akt by CMV can be detected 96 h after
infection, long term activation requires the expression of CMV proteins
during viral replication. Expression of CMV major immediate-early
protein 1 (IEP72) or 2 (IEP86) activates PI3K and Akt and inhibits
apoptosis (Cobbs et al., 2008; Yu and Alwine, 2002). PI3K activity is
required for upregulation of the anti-apoptotic protein c-FLIP by CMV
IEP86 (Chiou et al., 2006).
EBV encodes two immediate-early proteins BRLF1 and BZLF1
which are essential for lytic replication and reactivation from
latency. Overexpression of BRLF1, but not BZLF1, in normal human
ﬁbroblasts activates PI3K/Akt signaling (Darr et al., 2001). Activa-
tion of PI3K/Akt signaling is required for BRLF1 activation of the
BZLF1 and BMRF1 early promoters, but not the SM early promoter,
in epithelial cells.
KSHV G-protein-coupled receptor (vGPCR), transmembrane pro-
tein K1, and viral IL-6 (vIL-6) all activate PI3K/Akt. KSHV vGPCR
activates multiple signaling pathways including ERK, p38, NF-AT,
and PI3K (Bais et al., 1998; Cannon and Cesarman, 2004; Montaner
et al., 2001; Pati et al., 2003; Smit et al., 2002). Expression of KSHV
vGPCR results in translocation of Akt to the plasma membrane and
increased levels of bcl-2 mRNA and protein which inhibits apoptosis
(Abboud et al., 2013). Activation of PI3K/Akt by vGPCR results in
inactivation of GSK-3β and activation of NFAT which is a transcrip-
tion factor that mediates expression of inﬂammatory cytokines
(Bais et al., 1998; Cannon and Cesarman, 2004; Montaner et al.,
2001; Pati et al., 2003; Smit et al., 2002). PI3K/Akt activation by
GPCR also results in phosphorylation of TSC-2, mTOR, 4EPB1, and
S6K1 to enhance translation and cell proliferation (Sodhi et al.,
2006). Constitutive activation of Akt by vGPCR has an essential role
in KSHV sarcomagenesis (Sodhi et al., 2004). KSHV K1, which is a
functional mimic for BCR signaling, has a carboxyl terminal ITAM
motif and recruits Lyn, Syk, and the p85 subunit of PI3K to
constitutively activate PI3K/Akt (Prakash et al., 2005; Tomlinson
and Damania, 2004; Xue et al., 2014). KSHV K1 activation of Akt is
associated with phosphorylation and inhibition of FOX01, GSK3β,
and BAD which are important for inhibition of apoptosis, and
phosphorylation of mTOR which may increase translation and
endothelial cell transformation (Wang et al., 2006). K1 also inhibits
expression of PTEN, which inhibits the activity of PI3K. KSHV vIL-6
binds to its receptor gp130 to activate PI3K/Akt and the JAK2/STAT3
pathway which contributes to reprogramming of endothelial cells
to lymphatic cells (Morris et al., 2008; Morris et al., 2012). Expres-
sion of the KSHV immediate-early protein Rta, which is required for
reactivation from latency, also activates Akt (Li et al., 2012).
Activation of PI3K during herpesviruses latency and reactivation
Herpesviruses establish latency in different cell types with
limited or no expression of viral proteins. The PI3K/Akt pathway
is activated in cells latently infected with human herpesviruses,
and is important for both latency and reactivation. Additional
signaling pathways are also important for EBV and KSHV that
infect B cells to allow latent infection in these proliferating cells as
well as to inhibit apoptosis.
HSV latently infected neurons express no viral proteins, but do
express the latency-associated transcript (LAT) which is important for
virus reactivation. Mouse neuroblastoma cells stably expressing LAT
have higher levels of phosphorylated and total Akt and are more
resistant to apoptosis after serum starvation compared with cells not
expressing LAT (Li et al., 2010). Maintenance of HSV-1 latency
requires persistent PI3K activation which is established by binding
of nerve growth factor to the TrkA receptor tyrosine kinase (RTK)
(Camarena et al., 2010). The p110α subunit of PI3K is essential to
activate PDK1 and maintain HSV-1 latency; treatment of latently
infected neurons with inhibitors of PI3K results in HSV-1 reactivation.
Primary B cells latently infected and transformed with EBV
express EBV nuclear antigens (EBNAs) and latent membrane
proteins (LMPs) and have activated PI3K/Akt (Wlodarski et al.,
2005). LMP1 is a functional homolog of constitutive CD40 signal-
ing, and LMP2A is a mimic for constitutive BCR signaling; these
viral proteins activate multiple cell signaling pathways required to
initiate and maintain B cell transformation and virus latency. LMP1
is a transmembrane protein with intracellular carboxyl terminal
activating regions CTAR1 and CTAR2. The CTAR domains associate
with TNF receptor-associated factors (TRAFs) to activate multiple
signaling pathways including PI3K/Akt, NF-κB, MAPK, JNK, AP1,
and JAK/STAT that regulate cell growth and transformation
(Brinkmann and Schulz, 2006; Eliopoulos and Young, 2001; Lam
and Sugden, 2003; Mainou et al., 2007; Soni et al., 2007). The
CTAR1 domain of LMP1 associates with the p85 subunit of PI3K to
activate PI3K (Dawson et al., 2003) and contributes to transforma-
tion of rodent ﬁbroblasts and growth of EBV-positive nasophar-
yngeal carcinoma cells in soft agar (Mainou et al., 2005; Shair
et al., 2008). Similarly, survival and growth of LMP1 transgenic B
lymphocytes and lymphoma cells requires activation of Akt
signaling (Shair et al., 2007). LMP1 activation of PI3K/Akt results
in inactivation of FOXO3α, reduction of expression of DNA
damage-binding protein 1 (DDB1), and repression of the DNA
repair response which may increase genomic instability and the
risk of transformation (Chen et al., 2008). Activation of PI3K/Akt by
LMP1 is required for interleukin (IL)-10 production and phosphor-
ylation of GSK-3β and S6K1 (Lambert and Martinez, 2007).
LMP1 activation of Akt has an important role in preventing
apoptosis. Activation of PI3K/Akt by LMP1 inhibits apoptosis medi-
ated by TRAIL and increases expression of the anti-apoptotic c-FLIP
protein (Li et al., 2011). Akt inhibits translocation of the pro-
apoptotic protein Bax from the cytoplasm to the mitochondria;
Bax localization in the mitochondria results in cytochrome release
and apoptosis (Tsuruta et al., 2002). LMP1 activation of Akt/PI3K
and FOXO3 induces expression of miR-21 (Yang et al., 2013) and
upregulates Mcl-1 both of which reduce apoptosis (Kim et al.,
2012).
EBV LMP2A is a transmembrane protein expressed during
latency. LMP2A mimics BCR signaling and is important for EBV
latency and virus-induced oncogenesis (Fotheringham et al., 2012;
Scholle et al., 2000; Swart et al., 2000). LMP2A associates with Syk
and Lyn tyrosine kinases and with scaffold protein Shb to activate
Ras, PI3K and Akt (Fukuda and Longnecker, 2007; Matskova et al.,
2007; Swart et al., 2000). The ITAM motif of LMP2A is required for
activation of Akt (Morrison and Raab-Traub, 2005). Activation of
Akt increases the level of XIAP (Hatton et al., 2011) and BcLxL
(Portis and Longnecker, 2004) which increase survival of EBV-
infected B cells. LMP2A activation of Akt in nasopharyngeal
carcinoma cells results in activation of mTOR and phosphorylation
of 4EBP1 which enhances translation of cellular proteins (Moody
et al., 2005). LMP2A activation of Akt also increases survival of
epithelial cells (Scholle, Bendt et al. 2000) and inhibits apoptosis
mediated by TGF-β in epithelial and Burkitt lymphoma cells
(Fukuda, 2004). Activation of PI3K/Akt by LMP2A is important
for phosphorylation of FOXO1 and GSK-3β, and for translocation of
β-catenin to the nucleus of epithelial cells which may inhibit their
differentiation (Morrison et al., 2003). EBV latent EBNA-2 may also
contribute to P13K/Akt activation by induction of the p55α
regulatory subunit of PI3K (Spender et al., 2006).
Other mechanisms can lead to activation of Akt in EBV-infected
cells. EBV encodes microRNA miR-BART7-3p that targets PTEN,
enhances activation of Akt, and increases cell migration of naso-
pharyngeal carcinoma cells (Cai et al., 2014). Hypermethylation of
the promoter of INPP4B, a phosphatase that inhibits PI3K/Akt
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signaling, enhances the PI3K/Akt pathway in EBV-positive naso-
pharyngeal carcinoma cells (Yuen et al., 2014).
PI3K/Akt has an important role in EBV reactivation from
latency. Inhibition of PI3K reduces EBV reactivation induced by
BCR signaling in EBV-positive Burkitt lymphoma cell lines (Iwakiri
and Takada, 2004; Goswami et al., 2012). Similarly, blocking PI3K
impairs TGF-β-induced reactivation of EBV in Burkitt lymphoma
cells (Oussaief et al., 2009) and methotrexate-induced EBV reacti-
vation in lymphoblastoid cell lines (Feng et al., 2004).
Activation of PI3K/Akt by KSHV is important for survival of latently
infected primary effusion lymphoma cells (Uddin et al., 2005) and
monocytes (Gonnella et al., 2013), and for tubule formation in
endothelial cells (Wang and Damania, 2008). Akt activation contri-
butes to increased expression of XIAP, phosphorylation of FOXO1 and
GSK-3β, prevention of cytochrome c release from mitochondria, and
inhibition of cleavage of caspase-3, caspase-9, and PARP in KSHV-
positive primary effusion lymphoma cells (Uddin et al., 2005).
The KSHV latency associated proteins include LANA (ORF73), v-
cyclin (ORF72), v-FLIP (ORF71), Kaposins, LANA2, vIRF3, and K10.5.
Inhibition of PI3K activity results in increased cytoplasmic locali-
zation of LANA2 which may reduce the ability of LANA2 to block
apoptosis (Munoz-Fontela et al., 2005). KSHV v-FLIP induces
secretion of cytokines which activate Akt (Sharma-Walia et al.,
2012). Inhibition of Akt activity inhibits KSHV reactivation from
latently infected primary effusion lymphoma cells induced by
treatment with a p53 activator or a Cdk1 inhibitor, but enhances
KSHV reactivation induced by treatment with phorbol ester (TPA)
(Li et al., 2012; Peng et al., 2010). Inhibition of PI3K reduces KSHV
reactivation induced by BCR signaling in KSHV-positive Burkitt
lymphoma cell lines, and this effect is associated with reduced
expression of KSHV Rta (Kati et al., 2013).
Thus the PI3K/Akt pathway is critical for maintaining HSV, EBV,
and KSHV latent infection; inhibition of PI3K/Akt reduces EBV and
KSHV reactivation induced by BCR signaling, but enhances reacti-
vation of HSV and KSHV induced by treatment with other stimuli.
PI3K and immunodeﬁciencies
Recently two immunodeﬁciencies have been reported in asso-
ciation with mutations in the p110 catalytic or p85 regulatory
subunits of PI3K. Two groups have reported patients with severe
herpesvirus infections who have heterozygous gain-of-function
mutations in PIK3CD, which encodes PI3Kδ (Angulo et al., 2013;
Lucas et al., 2014a). These patients presented with fatal varicella-
zoster virus pneumonia, persistent CMV viremia, CMV lymphade-
nitis, persistent EBV viremia, EBV-positive B cell lymphomas, or
other infections including severe otitis, sinusitis, pneumonia, and
bacterial meningitis. They also had prominent lymphadenopathy,
nodular lymphoid hyperplasia, increased levels of IgM, and
impaired responses to vaccination. In each patient a dominant
gain-of-function mutation in one allele of PIK3CD resulted in
constitutive activation and phosphorylation of Akt and increased
activation of mTOR. The patients had reduced CD4 T cells, reduced
naïve T cells, reduced memory B cells, increased effector memory
T cells, increased senescent CD8 effector T cells, and enhanced
activation-induced T cell death. Treatment of one patient with
sirolimus reduced lymphoid hyperplasia, and increased naïve T
cells (Lucas et al., 2014a), while hematopoietic stem cell transplant
was curative in another patient (Angulo et al., 2013). The disease is
referred to as APDS (activated PI3K-delta syndrome (Angulo et al.,
2013)) or PASLI (p110delta-activating mutation causing senescent
T cells, lymphadenopathy, and immunodeﬁciency with mutations
in PIK3CD) (Lucas et al., 2014a). Additional patients have been
described with EBV-negative lymphomas and with infections due
to pathogens other than herpesviruses (Crank et al., 2014;
Hartman et al., 2014; Kracker et al., 2014).
Patients with heterozygous gain-of-function mutations in
PIK3R1, which encodes the p85 regulatory subunit of PI3K, were
reported with an immunodeﬁciency syndrome with recurrent
bacterial upper and lower respiratory tract infections (Deau
et al., 2014; Lucas et al. 2014b). One patient had persistent asympto-
matic CMV and EBV viremia as well as gastroenteritis due to
enterovirus. Like patients with mutations in PIK3CD, patients with
mutations in PIK3R1 also have increased phosphorylation of Akt,
increased mTOR signaling, increased IgM, reduced naïve T cells,
reduced memory B cell function, increased senescent CD8 T cells,
and enhanced activation-induced T cell death. The disease is referred
to as APDS2 (activated PI3Kdelta syndrome 2) or PASLI-R1
(p110delta-activating mutation causing senescent T cells, lymphade-
nopathy, and immunodeﬁciency with mutations in PIK3R1).
PI3K/Akt pathway in herpesvirus associated malignancies
EBV and KSHV are oncogenic viruses associated with B cell and
epithelial cell malignancies. PI3K/Akt is activated in EBV-positive
post-transplant lymphoproliferative disease, Hodgkin lymphoma,
nasopharyngeal carcinoma, and gastric carcinoma (Alsayed et al.,
2008; Chen, 2012). Similarly, the PI3K/Akt pathway is activated in
Kaposi's sarcoma and primary effusion lymphoma (Bhatt et al.,
2010; Sodhi et al., 2004; Uddin et al., 2005). Therefore, inhibition
of the PI3K/Akt pathway is a potential target for the treatment of
EBV and KSHV associated malignancies.
Targeting the PI3K/Akt pathway to inhibit virus replication and virus-
associated malignancies
While a number of small molecule inhibitors are available to
block PI3K/Akt activity in vitro and many of these have been
shown to inhibit herpesvirus replication, most of these drugs are
not licensed for use in humans. Recently miltefosine, which blocks
Akt phosphorylation, has been approved for use in leishmaniasis.
Pre-treatment of cultured cells with miltefosine, followed by HSV-
2 infection, inhibited virus plaque formation (Cheshenko et al.
2013). Further studies showed the miltefosine blocked virus entry
into epithelial cells, calcium release, and reactivation of virus from
explanted ganglia to epithelial cells. Miltefosine inhibited replica-
tion of acyclovir-sensitive and acyclovir- resistant HSV-2 strains.
Several PI3K inhibitors are currently in trials for treatment of
malignancies (Bauer et al., 2015; Blachly and Baiocchi, 2014; Tasian
et al., 2014). Recently, a small molecule inhibitor of PI3Kδ
(idelalisib) was approved for treatment of patients with relapsed
chronic lymphocytic leukemia and follicular B cell lymphoma
(Furman et al., 2014; Gopal et al., 2014). Thus, Akt or PI3K
inhibitors might be used for treatment of anti-viral resistant
herpesvirus infections in the future.
The PI3K/Akt pathway results in activation of mTOR. While
several mTOR inhibitors are in clinical trials for cancer therapy
(Bauer et al., 2015; Blachly and Baiocchi, 2014; Tasian et al., 2014),
at present only sirolimus (also known as rapamycin), everolimus,
and temserolimus are approved for use in humans. These drugs
are immunosuppressive and used in transplant recipients and for
treating selected malignancies. Sirolimus inhibits the growth of
KSHV primary effusion lymphoma cells in vitro (Sin et al., 2007).
Replacement of cyclosporine with sirolimus therapy in 15 kidney
transplant recipients with Kaposi's sarcoma resulted in the reso-
lution of Kaposi's sarcoma skin lesions (Stallone et al., 2005).
Substitution of calcineurin inhibitors with sirolimus in 14 patients
with post-transplant Kaposi's sarcoma resulted in complete remis-
sions in two patients and partial responses in 8 patients (Lebbe
et al., 2006). Similarly, a pooled analysis from several transplant
centers showed that substitution of immunosuppressive regimens
in 12 renal transplant recipients with regimens containing either
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sirolimus or everolimus resulted in resolution of Kaposi's sarcoma
lesions in 11 patients (Campistol and Schena, 2007).
Sirolimus also inhibits EBV-positive B cell lymphomas in a
xenogenic mouse model and in EBV LMP2/Myc transgenic mice
(Cen and Longnecker, 2011; Nepomuceno et al., 2003). In three
patients with EBV-associated post-transplant lymphoma, replace-
ment of calcineurin inhibitors and mycophenolate mofetil or
azathioprine with sirolimus resulted in complete resolution of B cell
lymphomas in two patients and a temporary remission of a T cell
lymphoma in one patient (Boratynska and Smolska, 2008). A pooled
analysis of 19 renal transplant recipients with post-transplant
lymphoproliferative disease from multiple European transplant cen-
ters showed that substitution of calcineurin inhibitors with sirolimus
or everolimus, along with rituximab therapy in six patients and
chemotherapy in six patients, resulted in complete remission of
disease in 15 patients (Pascual, 2007). While sirolimus has a partially
inhibitory effect on EBV-positive B cell lymphoma lines and resis-
tance to sirolimus is associated with high levels of phosphorylated
Akt, the addition of a PI3Kδ inhibitor to sirolimus enhanced the
ability of the latter to kill the cells (Furukawa et al., 2013). Similarly,
an experimental drug that inhibits both PI3K and mTOR was more
effective than either PI3K or mTOR inhibitors to inhibit the growth of
KSHV-positive primary effusion lymphoma cells in vitro and in a
xenograft tumor model (Bhatt et al., 2010).
Conclusions
Human herpesviruses express multiple proteins during the
immediate-early, early, and late phases of the virus replication
cycle and during latency that activate the PI3K/Akt pathway.
Activation of PI3K/Akt by viral glycoproteins such as gB in HSV,
CMV, and KSHV, HSV gD, and EBV gp350, as well as tegument
proteins of HSV and VZV present during herpesvirus entry is
important for preparing the cell for virus infection to optimize
virus replication. Similarly, activation of PI3K/Akt by immediate-
early proteins such as CMV IE1 and IE2, and Rta in EBV and KSHV
are important for the initial stages of virus infection. Herpesvirus
proteins expressed in the early phase of virus replication, such as
KSHV vIL-6 and vGPCR, also contribute to PI3/Akt activation. PI3K/
Akt is also critical for maintaining latent herpesvirus infection and
this pathway is activated by HSV LAT and the EBV latency proteins
LMP1, LMP2, and EBNA-2. PI3K-Akt signaling is required for
optimizing protein synthesis, cell growth, transformation, and
inhibiting apoptosis. Constitutive activation of PI3K due to muta-
tions in the cellular genes PIK3CD or PIK3R1 result in severe
herpesvirus infections due to impaired cellular immunity. PI3K/
Akt is activated in several EBV and KSHV associated B cell and
epithelial cell malignancies. Recently, several drugs that block Akt
or PI3K have been licensed for treatment of malignancies or for a
parasitic infection. These include miltefosine, which blocks Akt
phosphorylation and inhibits HSV in vitro and idelalisib, which
blocks PI3Kδ. These drugs, and others currently under develop-
ment, might be used to treat human herpesvirus infections or
virus-associated malignancies. Inhibitors of mTOR, such as siroli-
mus, everolimus, and temserolimus, which block signaling down-
stream of PI3K/Akt might also have a role in treating herpesvirus
infections. Thus, further studies and development of inhibitors of
the PI3K/Akt pathway may lead to novel therapies for both acute
herpesvirus infections and for virus-associated malignancies.
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